🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 42 of 116

  1. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  2. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Clifutinib Besylate

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  4. Clobetasol Propionate

    United Therapeutics Europe Ltd

    Colon Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  5. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  6. Cobimetinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  7. Colonoscopy with enhanced dye

    Cardiff Oncology

    Colorectal Cancer

    phase 2 other completed

    1 trial

  8. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  9. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  11. Combination of Bortezomib, Fludarabine and Cyclophosphamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 small molecule active

    1 trial

  12. Combination of MK3475 with Metronomic CP

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 small molecule completed

    1 trial

  13. Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

    United Therapeutics Europe Ltd

    Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Combination therapy (COMB)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  15. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  16. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  17. Coriolus Versicolor

    Hospital Authority, Hong Kong

    Carcinoma

    phase 2 small molecule terminated

    1 trial

  18. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  20. Cyclophosphamide

    Takeda

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

    phase 2 small molecule active

    1 trial

  21. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  22. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial

  23. Cyclophosphamide

    BEONE MEDICINES AUS PTY LTD

    Recurrent Transformed Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial

  25. Cyclophosphamide

    United Therapeutics Europe Ltd

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  26. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial

  27. Cyclophosphamide Doxorubicin Vincristine Lamivudine

    Taiwan Liposome Company

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  28. Cyclophosphamide+Pemetrexed+5-Fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Thyroid Gland Carcinoma

    phase 2 small molecule active

    1 trial

  29. Cyproterone acetate 5

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  30. Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig

    AstraZeneca AB

    metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  31. Cyramza 10 mg/ml concentrate for solution for infusion, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  32. Cytarabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  33. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  34. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Leukemia

    phase 2 small molecule terminated

    1 trial

  35. Cytarabine and Idarubicin

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  36. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  37. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  38. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial

  39. DARATUMUMAB , BORTEZOMIB , DEXAMETHASONE

    Fondazione Telethon ETS

    Relapsed or Refractory Plasmablastic lymphoma

    phase 2 small molecule active

    1 trial

  40. DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  41. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  42. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  43. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  44. DC1 Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 2 mab active

    1 trial

  45. DCC-3014, DCC-3014, DCC-3014

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  46. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  47. DCVax-Direct

    NORTHWEST BIOTHERAPEUTICS INC

    Locally Advanced Tumor

    phase 2 mab active

    1 trial

  48. DCVax-L and T Cells

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.